LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.
Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake has been developing a naloxone nasal spray that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the United States. In collaboration with NIDA, Lightlake will now evaluate its technology on a larger population, which will be a key step towards approval in the United States and other worldwide regions.
"We are extremely pleased that NIDA has continued its support of our opioid overdose reversal treatment," said Dr. Roger Crystal, CEO of Lightlake. "This support demonstrates NIDA's commitment of having an FDA approved intranasal naloxone nasal spray available to the public."
"NIDA's continued commitment to advancing our overdose reversal treatment reflects their confidence in the potential of our treatment," said Kevin Pollack, CFO of Lightlake. "We believe that our treatment can make a huge difference in addressing the overdose epidemic and save a significant number of lives, and NIDA's support plays a critical role in achieving our goals."
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has successfully completed a clinical trial for this treatment in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. Lightlake also has successfully completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Lightlake Therapeutics Inc.
Dr. Roger Crystal, CEO
+44(0)203 617 8739
Investor Relations Contact:
Booke and Company, Inc.
|SOURCE Lightlake Therapeutics Inc.|
Copyright©2014 PR Newswire.
All rights reserved